CCGB(SZ:300138)2023-10-23 16:00Financial Performance - The company's revenue for Q3 2023 was ¥1,500,747,199.05, a decrease of 4.36% compared to the same period last year[4]. - Net profit attributable to shareholders was ¥99,701,156.24, an increase of 3.46% year-on-year[4]. - The net profit excluding non-recurring gains and losses was ¥90,103,951.26, up by 1.99% compared to the previous year[4]. - The basic earnings per share for Q3 2023 was ¥0.19, representing a 5.56% increase year-on-year[4]. - Total operating revenue for Q3 2023 reached ¥5,169,444,187.28, an increase of 7.8% compared to ¥4,796,296,740.75 in Q3 2022[35]. - Net profit for Q3 2023 was ¥416,111,137.75, representing a 22.9% increase from ¥338,498,870.32 in Q3 2022[36]. - The company reported a comprehensive income total of ¥429,534,028.97 for Q3 2023, compared to ¥368,498,963.22 in Q3 2022, an increase of 16.5%[36]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥7,429,668,380.17, reflecting a growth of 7.31% from the end of the previous year[5]. - The company's total assets increased to ¥7,429,668,380.17 in Q3 2023, compared to ¥6,923,739,569.28 in Q3 2022, marking a growth of 7.3%[34]. - The company's total liabilities amounted to ¥3,873,496,476.58 in Q3 2023, compared to ¥3,709,657,856.10 in Q3 2022, reflecting a rise of 4.4%[34]. - Non-current assets totaled ¥2,137,135,551.84 in Q3 2023, up from ¥1,996,966,856.54 in Q3 2022, indicating an increase of 7.0%[34]. Cash Flow - The company's cash flow from operating activities showed a significant decline of 41.33%, totaling ¥995,638,605.50 year-to-date[4]. - Net cash flow from operating activities decreased by 41.33% year-on-year, primarily due to changes in various cash flow components from operating activities[14]. - Cash inflow from operating activities totaled ¥5,222,452,862.69, a decrease of 3.9% compared to ¥5,434,526,944.86 in Q3 2022[37]. - Net cash flow from operating activities was ¥995,638,605.50, down 41.4% from ¥1,697,041,867.19 in the previous year[37]. - Cash inflow from investment activities was ¥1,030,026,484.00, an increase of 21.8% compared to ¥845,698,510.93 in Q3 2022[38]. - Net cash flow from investment activities was -¥18,319,902.96, improving from -¥583,565,873.57 in the same period last year[38]. - Cash inflow from financing activities was ¥2,786,703,439.90, down 9.7% from ¥3,086,033,012.12 in Q3 2022[38]. - Net cash flow from financing activities was ¥289,159,193.02, compared to a negative cash flow of -¥121,883,835.12 in the previous year[38]. - The ending balance of cash and cash equivalents was ¥2,092,404,812.87, an increase from ¥1,754,948,773.44 at the end of Q3 2022[38]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,142[18]. - The largest shareholder, Lu Qingguo, holds 18.43% of shares, totaling 98,196,051 shares, with 73,647,038 shares pledged[18]. - The number of ordinary shareholders increased from 12,031 at the end of July 2023 to 12,657 at the end of August 2023[19]. Research and Development - Research and development expenses decreased by 37.75% compared to the same period last year, indicating a reduction in project investment[12]. - Research and development expenses for Q3 2023 were ¥61,110,369.60, down from ¥98,167,189.31 in Q3 2022, showing a decrease of 37.7%[36]. - The company is focusing on technology research and development, with ongoing projects aimed at improving production processes and product quality[28]. - The company is actively developing new products, including customized and specialized products to enhance customer solutions[24]. - The company has completed the development of new extraction processes for ginger and pepper, enhancing product competitiveness and profit margins[29]. - The company has launched several new products, including microencapsulated products and specialized application products, aimed at expanding its product range and market presence[29]. - The company has successfully registered new health food products, including fish oil soft capsules and coenzyme Q10 soft capsules, to enhance its market competitiveness[30]. - The company has made progress in the comprehensive utilization of chili, completing feasibility studies for new resource applications in food products[30]. - The company has developed a new extraction process for sophora japonica, improving the yield of rutin and addressing environmental concerns associated with traditional methods[30]. - The company has completed the production transformation of compound Danshen tablets and motherwort granules, expanding its traditional Chinese medicine product offerings[29]. - The company is actively conducting market research and product development to identify new profit growth points and enhance overall market competitiveness[29]. Inventory and Current Assets - The company optimized its inventory management, with inventory decreasing from CNY 2,033,380,620.48 to CNY 1,350,895,378.40, reflecting a reduction of approximately 33.7%[32]. - The total current assets reached CNY 5,292,532,828.33, up from CNY 4,926,772,712.74, indicating an increase of about 7.4%[32]. - As of September 30, 2023, the company's cash and cash equivalents increased to CNY 2,294,254,913.51 from CNY 1,146,656,571.64 at the beginning of the year, representing a growth of approximately 100%[32]. Other Income and Expenses - Other income increased by 113.41% year-on-year, driven by government grants and subsidies received during the reporting period[12]. - Other comprehensive income decreased by 55.26% compared to the same period last year, mainly due to reduced foreign currency translation differences from exchange rate fluctuations[14]. - Cash received from investment income increased by 313.87% year-on-year, attributed to dividends from associates and cash flow from short-term financial management[14]. - Net cash flow from investment activities increased by 96.86% year-on-year, driven by the recovery of financial management funds and returns exceeding the previous year[14]. - The cash received from other financing activities increased by 100% year-on-year, mainly due to increased cash inflow from pledged deposits[16]. - The impact of exchange rate fluctuations on cash decreased by 214.62% year-on-year, reflecting changes in foreign currency settlements in import and export businesses[16]. Company Overview - The company achieved a revenue of 5.169 billion yuan in the first three quarters of 2023, representing a year-on-year growth of 7.78%[23]. - The net profit attributable to shareholders reached 398 million yuan, an increase of 18.29% year-on-year[23]. - Sales from the chili red pigment segment grew by 15% year-on-year, while chili extract sales increased by 18%[23]. - The health food business generated over 100 million yuan in sales, marking a growth of over 70%[25]. - The company is expanding its raw material bases, with significant growth in planting areas in India and Zambia[26]. - The cottonseed business maintained steady operations, effectively managing raw material procurement and product sales[27]. - The company is promoting differentiated products and enhancing production efficiency in the stevia sugar segment[23]. Reporting and Audit - The company did not undergo an audit for the Q3 report[39]. - The report was released by the board of directors on October 23, 2023[40].